Answering clinicians' questions over trial evidence tables with verifiable, feedback-driven language models

We study clinical trial table reasoning, where answers are not directly stored in visible cells but must be reasoned from semantic understanding through normalization, classification, extraction, or lightweight domain reasoning. Motivated by the observation that current LLM approaches often suffer from "bad reasoning" under implicit planning assumptions, we focus on settings in which the model must recover implicit attributes such as therapy type, added agents, endpoint roles, or follow-up status from partially observed clinical-trial tables. We propose SCOPE (Structured Clinical hybrid Planning for Evidence retrieval in clinical trials), a multi-LLM planner-based framework that decomposes the task into row selection, structured planning, and execution. The planner makes the source field, reasoning rules, and output constraints explicit before answer generation, reducing ambiguity relative to direct prompting. We evaluate SCOPE on 1,500 hybrid reasoning questions over oncology clinical-trial tables against zero-shot, few-shot, chain-of-thought, TableGPT2, Blend-SQL, and EHRAgent. Results show that explicit multi-LLM planning improves accuracy for reasoning-based questions while offering a stronger accuracy-efficiency tradeoff than heavier agentic baselines. Our findings position clinical trial reasoning as a distinct table understanding problem and highlight hybrid planner-based decomposition as an effective solution

Structured extraction of evidence from clinical trial publications underpins systematic reviews and clinical guidelines, yet large language models are adopted for it only hesitantly: their outputs are difficult to verify, their use commonly requires transmitting documents to proprietary services, and they do not improve from the corrections their users make. We present EviSearch, a multi-agent system that addresses these three obstacles. Three tool-augmented agents with complementary access to a publication extract every column of an evidence table, and a value is admitted only after an attribution verifier has read it on its cited page, so that every value carries a page-level attribution. Disagreement between independent agents directs human review to the cells most likely to be wrong, and reviewer feedback refines the schema definitions and a curation knowledge base without updating model parameters. The agentic system runs entirely offline on open-weight models. On a clinician-annotated benchmark of randomized-trial publications, EviSearch attributes 100.0% of its values, reaches 91.70% accuracy autonomously, and reaches 95.22% after review of 15.6% of cells, exceeding random review of the strongest single agent at equal effort by 1.75 points.

Clinicians exploring oncology trial repositories often need ad-hoc, multi-constraint queries over biomarkers, endpoints, interventions, and time, yet writing SQL requires schema expertise. We demo FD-NL2SQL, a feedback-driven clinical NL2SQL assistant for SQLite-based oncology databases. Given a natural-language question, a schema-aware LLM decomposes it into predicate-level sub-questions, retrieves semantically similar expert-verified NL2SQL exemplars via sentence embeddings, and synthesizes executable SQL conditioned on the decomposition, retrieved exemplars, and schema, with post-processing validity checks. To improve with use, FD-NL2SQL incorporates two update signals: (i) clinician edits of generated SQL are approved and added to the exemplar bank; and (ii) lightweight logic-based SQL augmentation applies a single atomic mutation (e.g., operator or column change), retaining variants only if they return non-empty results. A second LLM generates the corresponding natural-language question and predicate decomposition for accepted variants, automatically expanding the exemplar bank without additional annotation. The demo interface exposes decomposition, retrieval, synthesis, and execution results to support interactive refinement and continuous improvement.